Idenix Pharmaceuticals, Inc.

Centre National De La Recherche Scientifique

Université Montpellier 2 Sciences Et Techniques

Merck Sharp + Dohme Corp.

Universitè De Montpellier

Biofocus Dpi, Ltd.

Christophe Parsy

Dominique Surleraux

Francois-Rene Alexandre

Cyril B Dousson

David Dukhan

Thierry Convard

Claire Pierra

Florence Marie-Emilie Bonnaterre

Michel Derock

Adel M Moussa

Gilles J Gosselin

Benjamin Alexander Mayes

Frederic Leroy

Houcine Rahali

Alistair James Stewart

Guillaume Brandt

Jean-Laurent Paparin

Daniel Da Costa

Jean-Christophe Meillon

Izzat Tiedje Raheem

Dale Robert Mitchell

Angus MacLeod

Clifford John Harris

Rachid Rahali

Nicholas John Palmer

Jean-Francois Griffon

Alistar James Stewart

Michael Daniel Goldsmith

Jean-François Griffon

The present invention is directed carbocyclic nucleoside reverse transcriptase inhibitors compounds of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC.

Carbocyclic nucleoside reverse transcriptase inhibitors

The present invention relates to novel nucleoside derivatives, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.

Nucleotides for the treatment of cancer

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2'-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.

2'-chloro nucleoside analogs for HCV infection

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2'-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, Rand Rare as described herein.

Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of HCV

Provided herein are compounds, compositions and methods for the treatment of liver cancer such as hepatocellular carcinoma, cholangiocarcinoma, or biliary tract cancer. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-cancer agents. In certain embodiments, the compounds are nucleoside analogs of Formula I: (I); or a pharmaceutically acceptable salt thereof, wherein Base, Z, Z, Z, Z, V, W, X, Ar, Rand Rare as described herein. 

Nucleotides for the treatment of liver cancer

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, and pharmaceutical compositions and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. 

Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3'-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Baseand Baseare as provided herein.

3'-deoxy nucleosides for the treatment of HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

3',5&#x2032;-cyclic phosphate prodrugs for HCV infection

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. 

Macrocyclic serine protease inhibitors

Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. 

5,5-fused arylene or heteroarylene hepatitis C virus inhibitors

Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst. 

Phosphinate ruthenium complexes

3',5&#x2032;-cyclic phosphoramidate prodrugs for HCV infection

Substituted 3',5&#x2032;-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections

Growing community of inventors

Jacou, France

Christophe Parsy